Technical Analysis for VTVT - vTv Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 2.71 -4.24% -0.12
VTVT closed down 4.24 percent on Thursday, January 17, 2019, on 30 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical VTVT trend table...

Date Alert Name Type % Chg
Jan 17 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 17 Inside Day Range Contraction 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 1,2,3 Pullback Bullish Bullish Swing Setup -4.24%
Jan 16 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.24%
Jan 16 Outside Day Range Expansion -4.24%
Jan 16 Wide Bands Range Expansion -4.24%
Jan 15 Narrow Range Bar Range Contraction 8.84%
Jan 15 NR7 Range Contraction 8.84%

Older signals for VTVT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
vTv Therapeutics Inc., a biopharmaceutical company, engages in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease includes azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. The company's type 2 diabetes drug candidates comprise TTP399, an orally administered, liver-selective glucokinase activator, which is in a Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor that has completed Phase I clinical trials. It is also developing HPP593, a functionally selective peroxisome proliferator-activated receptor delta agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury that has completed Phase Ib clinical trials; HPP737, an orally administered phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease, psoriasis, and other inflammatory diseases, which has completed Phase Ib clinical trials; and HPP971, a Bach1 inhibitor, for the treatment of inflammation, autoimmune diseases, and diseases associated with oxidative stress, which is in Phase 1 clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to research, develop, and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina.
Is VTVT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.4
52 Week Low 0.65
Average Volume 2,353,218
200-Day Moving Average 1.813
50-Day Moving Average 2.0608
20-Day Moving Average 2.231
10-Day Moving Average 2.728
Average True Range 0.4334
ADX 36.89
+DI 32.7931
-DI 12.3154
Chandelier Exit (Long, 3 ATRs ) 2.1998
Chandelier Exit (Short, 3 ATRs ) 2.3002
Upper Bollinger Band 3.6715
Lower Bollinger Band 0.7905
Percent B (%b) 0.67
BandWidth 129.134917
MACD Line 0.2478
MACD Signal Line 0.2093
MACD Histogram 0.0385
Fundamentals Value
Market Cap 26.27 Million
Num Shares 9.69 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -1.62
Price-to-Sales 535.97
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.13
Resistance 3 (R3) 3.13 2.99 3.06
Resistance 2 (R2) 2.99 2.88 2.99 3.04
Resistance 1 (R1) 2.85 2.82 2.78 2.85 3.01
Pivot Point 2.71 2.71 2.68 2.71 2.71
Support 1 (S1) 2.57 2.60 2.50 2.57 2.41
Support 2 (S2) 2.43 2.54 2.43 2.38
Support 3 (S3) 2.29 2.43 2.36
Support 4 (S4) 2.29